Biotalys has published its annual (financial) report for 2022. A loss of 22.7 million euros was recorded for 2022. In 2021, it was 16.9 million euros. Biotalys is listed on the stock exchange. The company develops crop protection products, including the protein-based biofungicide Evoca. It wants to enter the US market with this, but it has been delayed.
Biotalys expects to have enough cash on board to last until 2024. Registration of Evoca for the US market is expected in the third quarter. The company does point out that the first generation of the biofungicide counts as a "market calibration product," from which positive cash flow margins are not expected. The market launch will need to generate market demand and allow growers to become acquainted with the product. A commercial, profitable version should be on the market by 2026.
Evoca's targets include mildew and botrytis control in strawberry cultivation.
For more information: